Mozart Ther­a­peu­tics se­cures $25M ex­pan­sion to Se­ries A; Lian­Bio un­veils PhI­Ia da­ta for gas­tric can­cer treat­ment

Mozart Ther­a­peu­tics, a Seat­tle-based biotech cen­tered on de­vel­op­ing CD8 treg mod­u­la­tors to treat au­toim­mune and in­flam­ma­to­ry dis­eases, has raised $25 mil­lion from new in­vestors to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER